Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04593758
Title To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613 (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Rafael Pharmaceuticals Inc.
Indications

Ewing sarcoma

clear cell sarcoma

sarcoma

Therapies

CPI-613 + Hydroxychloroquine

Age Groups: adult | child | senior
Covered Countries USA


No variant requirements are available.